A proposed common spatial pharmacophore and the corresponding active conformations of some peptide leukotriene receptor antagonists
- 1 August 1996
- journal article
- research article
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 10 (4), 284-292
- https://doi.org/10.1007/bf00124498
Abstract
Summary Molecular modeling studies were carried out by a combined use of conformational analysis and 3D-QSAR methods to identify molecular features common to a series of hydroxyacetophenone (HAP) and non-hydroxyacetophenone (non-HAP) peptide leukotriene (pLT) receptor antagonists. In attempts to develop a ligand-binding model for the pLT receptor, the Apex-3D program was used to identify biophoric structural patterns that are common to 13 diverse sets of compounds showing different levels of biological activity. A systematic conformational analysis was carried out to obtain sterically accessible conformations for these flexible compounds. Apex-3D was then utilized to propose common biophoric regions based on the selection of one of several conformations (MOPAC-minimized AM1) from each compound's data set that best fits the biophoric pattern and the resulting superimposition with all the other data-set compounds. Apex-3D identified three common biophoric features important for activity: one as the hydroxyl, acetyl, carbonyl and carboxyl groups, which mimic the acid-binding region of an agonist, the other as the hydrogen-bond donating site, and the third part is represented by a plane in which lipophilic aromatic groups align. The structure-activity relationships were then assessed by using the 3D-QSAR model. A common biophore model is proposed from the Apex-3D analysis which may be useful in designing new pLT antagonists. Molecular volumes and electrostatic potential similarities were also calculated in order to obtain the important structural requirements for the activity.Keywords
This publication has 21 references indexed in Scilit:
- Atomic charges for variable molecular conformationsJournal of the American Chemical Society, 1992
- Peptide leukotrienes: current status of researchJournal of Medicinal Chemistry, 1991
- Probes for narcotic receptor mediated phenomena. 17. Synthesis and evaluation of a series of trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide (U50,488) related isothiocyanate derivatives as opioid receptor affinity ligandsJournal of Medicinal Chemistry, 1990
- Semiempirical AM1 electrostatic potentials and AM1 electrostatic potential derived charges: A comparison with ab initio valuesJournal of Computational Chemistry, 1990
- Leukotriene receptor antagonists. 4. Synthesis and leukotriene D4/E4 receptor antagonist activity of 4-(alkyl)acetophenone derivativesJournal of Medicinal Chemistry, 1988
- Leukotrienes and Lipoxins: Structures, Biosynthesis, and Biological EffectsScience, 1987
- Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular modelJournal of the American Chemical Society, 1985
- Leukotrienes and Other Lipid Mediators of AsthmaChest, 1985
- Leukotrienes: Mediators of Immediate Hypersensitivity Reactions and InflammationScience, 1983
- A review of recent contributions on biologically active products of arachidonate conversionInternational Journal of Immunopharmacology, 1982